New in Future Oncology journal: COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Read the full article at https://lnkd.in/exMdsUpQ #CMPX #biotech #biopharmaceutical #oncology
Compass Therapeutics Inc.
Biotechnology Research
Boston, MA 7,302 followers
We are developing next-generation antibodies into transformative cancer therapies that improve patients’ lives.
About us
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. To learn more, visit www.compasstherapeutics.com
- Website
-
http://www.compasstherapeutics.com
External link for Compass Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2014
- Specialties
- Drug Discovery and Development, Biologics, Oncology, and Immuno-Oncology
Locations
-
Primary
Get directions
80 Guest Street
Suite 601
Boston, MA 02135, US
Employees at Compass Therapeutics Inc.
Updates
-
Join Compass Therapeutics CEO, Thomas Schuetz, MD, PhD, at the Jefferies Global Healthcare Conference 2024 for a Fireside Chat on June 5 at 1 p.m. ET. ➡️ In-person: Track 2 - Plymouth, 6th Floor ➡️ Online: Register for the webcast at https://bit.ly/3KkjpbF #CMPX #Biotech #Biotechnology #JefferiesHealthcare
-
-
At the 2024 ASCO Annual Meeting, we'll present data from the Phase 1 Study of our novel anti-CD137 antibody, CTX-471, and its safety and anti-tumor activity in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies. Clinical responses observed to date demonstrate the potential of our novel anti-CD137 antibody in patients with advanced refractory malignancies who have limited treatment options. Read more: https://ow.ly/QE7550RTQi4 With Thomas Schuetz. #CMPX #ASCO24 #biotech #biotechnology #healthcare #immunotherapy
-
-
Join Vered Bisker-Leib, PhD, Compass Therapeutics CEO, in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, at 11:30 a.m. ET. Register now for the live Webcast at https://ow.ly/nGPW50REL6V #CMPX #biotech #biopharmaceutical #HCWCO
-
-
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update https://ow.ly/cYxN50REmE3 #CMPX #biotech #biotechnology #healthcare
-
-
COMPANION-002, our Biliary Tract Cancer clinical trial, was recently covered by CCA News. Read the full article at: https://ow.ly/C5ae50RzK8s #CMPX #biotech #biotechnology #healthcare #cholangiocarcinoma #biliarytractcancer #ASCOGI24
COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC | CCA News Online
ccanewsonline.com
-
Sharing the latest article on our COMPANION-002 study of CTX-009. Thank you, Roswell Park Comprehensive Cancer Center!
A new phase 2/3 clinical trial for patients with advanced or metastatic biliary tract cancer, led by Dr. Renuka Iyer, builds off promising results from an earlier study assessing the combination of the chemotherapy drug paclitaxel and a bispecific antibody, CTX-009. The open-label, two-arm trial, sponsored by Compass Therapeutics Inc., is ongoing. Read more here: https://lnkd.in/g8BjwwNC.
-
-
Don't miss this from the Cholangiocarcinoma Foundation: Watch now!
ICYMI: In a past CCF Webinar, Dr. Thomas Schuetz, President of R&D at Compass Therapeutics Inc. discussed the Investigational Drug CTX-009 and the Phase 2/3 Biliary Tract Cancer Clinical Trial with Mitesh Borad, M.D. from Mayo Clinic. It was an excellent discussion so make sure to watch the recording. All of our past webinars are available on our YouTube channel. Tune in here: https://lnkd.in/gpN-6uj7
CCF Webinar: Investigational Drug CTX-009 & the COMPANION-002 Study of CTX-009 in patients with BTC
https://www.youtube.com/
-
We are at the Cholangiocarcinoma Foundation Annual Conference in Salt Lake City! We are honored to present our trial in progress and translational research posters. This conference is a wonderful opportunity for patients, industry, and clinicians to come together in a collective effort to create hope and share research about biliary tract cancers. To view our posters, see here: cmpx.info/posters #CMPX #ccfac24 #cholangiocarcinoma #ccahope
-
-
Join Vered Bisker-Leib, PhD, Compass Therapeutics CEO, as she presents at the Stifel 2024 Targeted Oncology Days on Tuesday, April 16, at 11 a.m. ET. Register now for the live webcast and post-event replay at CMPX.info/stifel. #CMPX #biotech #biopharmaceutical #oncology #healthcare
-